58142-99-7

Basic information

• Product Name: Isoquinoline, 5-iodo- (9CI)
• Synonyms: Isoquinoline, 5-iodo- (9CI);Isoquinoline, 5-iodo-
• CAS NO: 58142-99-7
• Molecular Formula: C₉H₆IN
• Molecular Weight: 255.05511
• EINECS: 604-604-1
• Product Categories: ISOQUINOLINE
• Mol File: 58142-99-7.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C(protect from light)
• CAS DataBase Reference: Isoquinoline, 5-iodo- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Isoquinoline, 5-iodo- (9CI)(58142-99-7)
• EPA Substance Registry System: Isoquinoline, 5-iodo- (9CI)(58142-99-7)

Safety Data

• Hazardous Substances Data: 58142-99-7(Hazardous Substances Data)

Usage

General Description

"Isoquinoline, 5-iodo- (9CI)" is a chemical compound often used in the creation of medicinal drugs due to its unique structural properties. Chemically, it has an isoquinoline structure which is a heterocyclic aromatic system, making it a base component for many pharmaceutical compounds. The addition of iodine at the 5th carbon in the ring adds another level of reactivity to the compound, further increasing its potential uses in chemical synthesis. Often, it is used to create medicinal compounds with anti-inflammatory, antiallergenic, or even anticancer properties. However, like all chemicals, it should be handled properly to ensure safety.

Upstream product

• 696-41-3 m-iodobenzaldehyde 
• 541-41-3 chloroformic acid ethyl ester 
• 22483-09-6 2,2-dimethoxyethylamine 
• 119-65-3 isoquinoline 
• 1125-60-6 isoquinolin-5-ylamine 
• 34784-04-8 5-bromoisoquinoline 

Downstream Products

• 856832-08-1 4-iodophthalimide 
• 6937-34-4 3-iodophthalic acid 
• 401916-13-0 5-iodo-8-nitroisoquinoline 
• 939758-80-2 5-iodo-1,2,3,4-tetrahydroisoquinoline 
• 1474060-71-3 1-(5'-isoquinolinyl)-1-(3'',4'',5''-trimethoxyphenyl)ethylene 
• 369652-57-3 2-(8-isoquinolineamino)-3-nitrobenzoic acid 

Relevant articles and documents

Cu(II)-Catalyzed Construction of Heterobiaryls using 1-Diazonaphthoquinones: A General Strategy for the Synthesis of QUINOX and Related P,N Ligands

An efficient and straightforward method was developed for the synthesis of heterobiaryls using easily available N-oxides and diazonaphthoquinones under cheap Cu(II) catalysis. The developed method offered QUINOX and related congeners in a simple manner. A wide scope of important heterobiaryls was achieved with high site selectivity. The synthesized naphthols were transformed into the privileged related P,N ligands. Suitable resolution methods can directly afford the corresponding axially chiral heterobiaryls.

High-yield synthesis method of 5-iodoisoquinoline compound

The invention relates to a high-yield synthesis method of a 5-iodoisoquinoline compound. The method comprises the following steps: carrying out a stirring reaction on an isoquinoline compound, N-iodosuccinimide and an acid solution in a nitrogen atmosphere at a reaction temperature of 5 DEG C or below for 1-5 hours; after the reaction is finished, adding an alkali solution, and performing stirringto quench the reaction; and carrying out aftertreatment to obtain the 5-iodoisoquinoline compound, wherein the isoquinoline compound is isoquinoline, alkyl-substituted isoquinoline or halogen-substituted isoquinoline. According to the method, the 5-iodoisoquinoline compound can be prepared with high efficiency and high yield, the yield of the 5-position iodine substituted product is 80 wt% or more, the yield of the 5-iodoisoquinoline compound product is still 75wt% or more even in a pilot plant test process, and the method has high industrial application value and is suitable for industrial batch production.

ARYL LINKED IMIDAZOLE AND TRIAZOLE DERIVATIVES AND METHODS OF USE THEREOF FOR IMPROVING THE PHARMACOKINETICS OF A DRUG

The present invention relates to aryl linked imidazole and triazole derivatives, compositions comprising said compounds, alone or in combination with other drugs, and methods of using the compounds for improving the pharmacokinetics of a drug. The compounds of the invention are useful in human and veterinary medicine for inhbiting CYP3A4 and for improving the pharmacokinetics of a therapeutic compound that is metabolized by CYP3A4.